Amy Daliman, DO
Cardiovascular Disease · Mesa, AZNPI 1326333733
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,000 of the $66,604 with a category attached, or 76.6%. Abiomed accounts for 89.8% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2024 at $31,439 and has fallen 98.4% since, to $492 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $348.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$60K
- Edwards Lifesciences$2K
- Penumbra, Inc.$1K
- Medtronic$647
- Boston Scientific$622
- Heartflow, Inc.$350
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$51,00077%
- Travel & lodging$8,74613%
- Food & beverage$6,81910%
- Other$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 57 | $59,811 |
| Edwards Lifesciences | 12 | $1,634 |
| Penumbra, Inc. | 3 | $1,450 |
| Medtronic(2 entities) | 11 | $647 |
| Boston Scientific | 26 | $622 |
| Heartflow, Inc. | 6 | $350 |
| Abbott | 15 | $344 |
| Philips North America LLC | 2 | $278 |
| Cleerly, Inc. | 4 | $163 |
| E.r. Squibb & Sons, L.L.C. | 11 | $160 |
| Bard Peripheral Vascular, Inc. | 2 | $144 |
| Impulse Dynamics (USA) Inc. | 1 | $131 |
| Atricure, Inc. | 2 | $110 |
| Angiodynamics, Inc. | 4 | $95 |
| Novartis | 4 | $81 |
| Pfizer | 5 | $76 |
| Teleflex LLC | 3 | $65 |
| Baxter Healthcare | 2 | $63 |
| EKOS Corporation | 3 | $48 |
| AstraZeneca | 3 | $48 |
| Acutus Medical, Inc. | 1 | $37 |
| Amgen | 2 | $34 |
| Itamar Medical Inc | 1 | $24 |
| Johnson & Johnson | 2 | $24 |
| Merck | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Terumo Medical Corporation | 1 | $18 |
| Reflow Medical Inc | 1 | $18 |
| Chiesi USA, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$59,006
- Indigo System$1,344
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,196
- CoreValve Evolut$278
- OPTIMIZER$262
- FFRct$256
- Spectranetics Undiv$250
- Resolute$191
- SAPIEN 3 Ultra RESILIA$124
- Penumbra System$106
- Indigo$106
- SYNERGY$102
How this compares
$66,604 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 389 | $499,118 |
| EntrestoSacubitril/Valsartan | 74 | $103,330 |
| XareltoRivaroxaban | 57 | $82,511 |
| BrilintaTicagrelor | 28 | $28,992 |
| ClopidogrelClopidogrel Bisulfate | 489 | $6,325 |
| Metoprolol Succinate | 511 | $6,179 |
| Ranolazine ErRanolazine | 49 | $4,909 |
| Atorvastatin Calcium | 452 | $4,769 |
| Rosuvastatin Calcium | 355 | $4,431 |
| Valsartan | 136 | $3,303 |
| Losartan Potassium | 282 | $3,264 |
| Digoxin | 27 | $2,466 |
| Nebivolol Hcl | 38 | $2,267 |
| Carvedilol | 208 | $2,127 |
| Nifedipine ErNifedipine | 25 | $1,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $499,118389 claims |
| NovartisEntresto | $81 | $103,33074 claims |
| Johnson & JohnsonXarelto | $24 | $82,51157 claims |
| AstraZenecaBrilinta | $48 | $28,99228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Mesa
- Andrew KaplanMesa$204K
- Rodrigo ChanMesa$81K
- Edgardo Zavala AlarconMesa$72K
- Charles JostMesa$50K
- Santosh DesaiMesa$26K
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Steven MottlTucson$340K
- Paul UnderwoodScottsdale$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.